Jun 04, 2024
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM
Jun 04, 2024
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
Jun 01, 2024
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
May 23, 2024
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates
Apr 24, 2024
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
Apr 07, 2024
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
Mar 27, 2024
Ascentage Pharma Announces 2023 Annual Results
Mar 05, 2024
AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
Feb 13, 2024
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
Jan 16, 2024
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)
Jan 10, 2024
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
Jan 01, 2024
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference
Feb 02, 2021
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
Jan 13, 2021
Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference
Jan 04, 2021
Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies
Dec 30, 2020
Ascentage Pharma Officially Included in Shenzhen-Hong Kong Stock Connect Program
Dec 11, 2020
PharmaBlock Enters Strategic Partnership with Ascentage Pharma
Dec 09, 2020
Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Dec 07, 2020
Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting
Dec 03, 2020
Ascentage Pharma Appoints Mr. Gang Zhu as Chief Commercial Officer to Lead Commercial Initiatives